Consequently, we designed the EMpagliflozin to PREvent worSening of left ventricular volumes and Systolic function after Myocardial Infarction (EMPRESS‐MI) randomized, placebo‐controlled trial to test the hypothesis that the SGLT2 inhibitor empagliflozin, in addition to current evidence‐based therapy, will attenuate adverse left ventricular remodelling measured using cardiovascular magnetic resonance (CMR) imaging in high‐risk patients following MI. This evidence concerns the gene SLC5A2 and myocardial infarction.